Published in Mol Cell on January 07, 2005
A mechanosensitive transcriptional mechanism that controls angiogenesis. Nature (2009) 3.44
Signal-induced functions of the transcription factor TFII-I. Biochim Biophys Acta (2007) 1.22
Crosstalk between the p190-B RhoGAP and IGF signaling pathways is required for embryonic mammary bud development. Dev Biol (2007) 1.04
Inhibition of TFII-I-dependent cell cycle regulation by p53. Mol Cell Biol (2005) 1.00
Biochemistry and biology of the inducible multifunctional transcription factor TFII-I: 10 years later. Gene (2011) 1.00
Interaction of p190RhoGAP with C-terminal domain of p120-catenin modulates endothelial cytoskeleton and permeability. J Biol Chem (2013) 0.95
Drosophila Rho-kinase (DRok) is required for tissue morphogenesis in diverse compartments of the egg chamber during oogenesis. Dev Biol (2006) 0.94
The FF domains of yeast U1 snRNP protein Prp40 mediate interactions with Luc7 and Snu71. BMC Biochem (2008) 0.93
RhoA is down-regulated at cell-cell contacts via p190RhoGAP-B in response to tensional homeostasis. Mol Biol Cell (2013) 0.87
PKCdelta influences p190 phosphorylation and activity: events independent of PKCdelta-mediated regulation of endothelial cell stress fiber and focal adhesion formation and barrier function. Biochim Biophys Acta (2009) 0.86
Interplay between FAK, PKCδ, and p190RhoGAP in the regulation of endothelial barrier function. Microvasc Res (2011) 0.86
Genomic and proteomic analysis of transcription factor TFII-I reveals insight into the response to cellular stress. Nucleic Acids Res (2014) 0.83
The GTPase-deficient Rnd proteins are stabilized by their effectors. J Biol Chem (2012) 0.81
P190A RhoGAP is required for mammary gland development. Dev Biol (2011) 0.81
Crystal structure of the three tandem FF domains of the transcription elongation regulator CA150. J Mol Biol (2009) 0.79
GTF2IRD2 from the Williams-Beuren critical region encodes a mobile-element-derived fusion protein that antagonizes the action of its related family members. J Cell Sci (2012) 0.78
The nuclear localization pattern and interaction partners of GTF2IRD1 demonstrate a role in chromatin regulation. Hum Genet (2015) 0.78
The human papillomavirus E7 proteins associate with p190RhoGAP and alter its function. J Virol (2014) 0.78
The N-terminal helix controls the transition between the soluble and amyloid states of an FF domain. PLoS One (2013) 0.77
Rho/RacGAPs: embarras de richesse? Small GTPases (2012) 0.76
Interaction of p190A RhoGAP with eIF3A and Other Translation Preinitiation Factors Suggests a Role in Protein Biosynthesis. J Biol Chem (2016) 0.75
A single cysteine post-translational oxidation suffices to compromise globular proteins kinetic stability and promote amyloid formation. Redox Biol (2017) 0.75
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78
Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy (2007) 20.92
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature (2012) 15.91
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol (2009) 15.23
Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer (2007) 14.84
Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med (2008) 13.54
Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science (2004) 11.58
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol (2008) 9.43
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A (2007) 8.23
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A (2005) 6.82
Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res (2008) 6.71
Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med (2010) 6.38
Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res (2008) 6.05
Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A (2006) 5.23
Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet (2008) 5.07
EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov (2012) 4.72
p120-catenin and p190RhoGAP regulate cell-cell adhesion by coordinating antagonism between Rac and Rho. Cell (2006) 4.24
Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev (2007) 4.11
Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet (2005) 4.00
A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell (2006) 3.78
A rapid and scalable system for studying gene function in mice using conditional RNA interference. Cell (2011) 3.69
SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature (2011) 3.69
Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr Opin Genet Dev (2008) 3.67
Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell (2012) 3.39
Modulation of Rho GTPase signaling regulates a switch between adipogenesis and myogenesis. Cell (2003) 3.36
BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci Signal (2010) 3.25
Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation. Cancer Res (2007) 2.78
TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc Natl Acad Sci U S A (2010) 2.72
Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy. Cancer Res (2011) 2.71
Transitions between epithelial and mesenchymal states in development and disease. Semin Cell Dev Biol (2008) 2.69
DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma. Genes Dev (2008) 2.60
The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor. Mol Cancer Ther (2008) 2.58
Repressive LTR nucleosome positioning by the BAF complex is required for HIV latency. PLoS Biol (2011) 2.49
STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. Cancer Res (2011) 2.35
Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib. Cancer Res (2007) 2.30
"Oncogenic shock": explaining oncogene addiction through differential signal attenuation. Clin Cancer Res (2006) 2.30
GAP control: regulating the regulators of small GTPases. Trends Cell Biol (2004) 2.21
Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. J Clin Invest (2011) 2.20
Inhibition of gamma-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology (2009) 2.17
Atg1-mediated myosin II activation regulates autophagosome formation during starvation-induced autophagy. EMBO J (2010) 2.12
DOCK4, a GTPase activator, is disrupted during tumorigenesis. Cell (2003) 1.94
Rnd proteins function as RhoA antagonists by activating p190 RhoGAP. Curr Biol (2003) 1.84
Opposing functions of TFII-I spliced isoforms in growth factor-induced gene expression. Mol Cell (2006) 1.81
Modeling oncogene addiction using RNA interference. Proc Natl Acad Sci U S A (2008) 1.79
The complexity of targeting EGFR signalling in cancer: from expression to turnover. Biochim Biophys Acta (2006) 1.75
TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma. Sci Transl Med (2013) 1.67
Towards patient-based cancer therapeutics. Nat Biotechnol (2010) 1.63
Modulation of CREB activity by the Rho GTPase regulates cell and organism size during mouse embryonic development. Dev Cell (2002) 1.58
Regulation of primary response genes. Mol Cell (2011) 1.56
Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers. Oncotarget (2011) 1.55
Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors. Cancer Res (2009) 1.54
Integrin signaling through Arg activates p190RhoGAP by promoting its binding to p120RasGAP and recruitment to the membrane. Mol Biol Cell (2006) 1.54
Activated Kras, but not Hras or Nras, may initiate tumors of endodermal origin via stem cell expansion. Mol Cell Biol (2008) 1.53
SHP-2 positively regulates myogenesis by coupling to the Rho GTPase signaling pathway. Mol Cell Biol (2004) 1.53
A structure-guided approach to creating covalent FGFR inhibitors. Chem Biol (2010) 1.46
Activation of PI3K signaling in Merkel cell carcinoma. Clin Cancer Res (2012) 1.45
p190RhoGAP is the convergence point of adhesion signals from alpha 5 beta 1 integrin and syndecan-4. J Cell Biol (2008) 1.41
Reactivation of latent HIV by histone deacetylase inhibitors. Trends Microbiol (2013) 1.35
Inhibition of Rho via Arg and p190RhoGAP in the postnatal mouse hippocampus regulates dendritic spine maturation, synapse and dendrite stability, and behavior. J Neurosci (2007) 1.33
p190 Rho-GTPase activating protein associates with plexins and it is required for semaphorin signalling. J Cell Sci (2005) 1.31
Adhesion-dependent regulation of p190RhoGAP in the developing brain by the Abl-related gene tyrosine kinase. Curr Biol (2004) 1.30
Genetic interactions between Drosophila melanogaster Atg1 and paxillin reveal a role for paxillin in autophagosome formation. Autophagy (2007) 1.30
A kinase shRNA screen links LATS2 and the pRB tumor suppressor. Genes Dev (2011) 1.30
Isoform-specific ras functions in development and cancer. Future Oncol (2009) 1.29
Essential functions of the Williams-Beuren syndrome-associated TFII-I genes in embryonic development. Proc Natl Acad Sci U S A (2008) 1.28
A chemical biology approach to developing STAT inhibitors: molecular strategies for accelerating clinical translation. Oncotarget (2011) 1.26
Mutational activation of ErbB family receptor tyrosine kinases: insights into mechanisms of signal transduction and tumorigenesis. Bioessays (2007) 1.26
Breast tumor kinase phosphorylates p190RhoGAP to regulate rho and ras and promote breast carcinoma growth, migration, and invasion. Cancer Res (2008) 1.26
Targeting aberrant glutathione metabolism to eradicate human acute myelogenous leukemia cells. J Biol Chem (2013) 1.25
EGF receptor inhibition radiosensitizes NSCLC cells by inducing senescence in cells sustaining DNA double-strand breaks. Cancer Res (2011) 1.24
p190-B RhoGAP regulates mammary ductal morphogenesis. Mol Endocrinol (2003) 1.23
Thy-1 regulates fibroblast focal adhesions, cytoskeletal organization and migration through modulation of p190 RhoGAP and Rho GTPase activity. Exp Cell Res (2004) 1.20
The Drosophila ATM ortholog, dATM, mediates the response to ionizing radiation and to spontaneous DNA damage during development. Curr Biol (2004) 1.19
Physical and functional interactions of histone deacetylase 3 with TFII-I family proteins and PIASxbeta. Proc Natl Acad Sci U S A (2002) 1.16
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers. Cancer Res (2010) 1.13
EGFR ligands exhibit functional differences in models of paracrine and autocrine signaling. Growth Factors (2012) 1.13
Increased prevalence of EGFR-mutant lung cancer in women and in East Asian populations: analysis of estrogen-related polymorphisms. Clin Cancer Res (2008) 1.12
GAPs in growth factor signalling. Growth Factors (2005) 1.12
Transcriptional regulation of the Grp78 promoter by endoplasmic reticulum stress: role of TFII-I and its tyrosine phosphorylation. J Biol Chem (2005) 1.12
High-throughput lung cancer cell line screening for genotype-correlated sensitivity to an EGFR kinase inhibitor. Methods Enzymol (2008) 1.11
Regulation of immunoglobulin promoter activity by TFII-I class transcription factors. J Biol Chem (2003) 1.09
Phospholipids can switch the GTPase substrate preference of a GTPase-activating protein. J Biol Chem (2003) 1.08
c-Src-dependent transcriptional activation of TFII-I. J Biol Chem (2002) 1.08
Histone deacetylase 3 binds to and regulates the multifunctional transcription factor TFII-I. J Biol Chem (2002) 1.08
Induction of immunoglobulin heavy-chain transcription through the transcription factor Bright requires TFII-I. Mol Cell Biol (2006) 1.07
ErbBs in lung cancer. Exp Cell Res (2008) 1.07
The complex of TFII-I, PARP1, and SFPQ proteins regulates the DYX1C1 gene implicated in neuronal migration and dyslexia. FASEB J (2008) 1.06
Regulation of Rho and Rac signaling to the actin cytoskeleton by paxillin during Drosophila development. Mol Cell Biol (2005) 1.05
Crosstalk between the p190-B RhoGAP and IGF signaling pathways is required for embryonic mammary bud development. Dev Biol (2007) 1.04
p190A RhoGAP is a glycogen synthase kinase-3-beta substrate required for polarized cell migration. J Biol Chem (2008) 1.03